Advertisement

Insulin-Like Growth Factor (IGF) Binding Protein-1 is an Antigonadotropin: Evidence that Optimal Follicle-Stimulating Hormone Action in Ovarian Granulosa Cells is Contingent upon Amplification by Endogenously-Derived IGFs

  • Eli Y. Adashi
  • C. E. Resnick
  • R. G. Rosenfeld
  • D. R. Powell
  • R. Koistinen
  • E. M. Rutanen
  • M. Seppala
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 343)

Abstract

Implicit in the antigonadotropic property of IGFBPs is the presumption that they sequester endogenously-generated IGFs thereby diminishing their access to cognate cell surface receptors and hence their cellular hormonal action. This communication examines this concept and the relevance of endogenous IGF to FSH action.

Key Words

IGF Ovary Binding Proteins Gonadotropins 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    E.-M. Rutanen, T. Karkkainen, C. Lundqvist, F. Pekonen, 0. Ritvos, E. Tanner, M. Weiin, and T. Weber, Monoclonal antibodies to the 27–34K insulin-like growth factor binding protein, Biochem. Biophys. Res. Commun. 152:208–215 (1988).PubMedCrossRefGoogle Scholar
  2. 2.
    E.Y. Adashi, C.E. Resnick, M.E. Svoboda, and J.J. Van Wyk, Somaiomedin-C as an amplifier of follicle stimulating hormone action: Enhanced accumulation of adenosine 3’,3’-cyclic monophosphate, Endocrinology 118:149–156, (1986).PubMedCrossRefGoogle Scholar
  3. 3.
    D.R. Clemmons, R.G. Elgin, V.K.M. Han, S.J. Casella, A.J. D’Ercole, and J.J. Van Wyk, Cultured fibroblast monolayers secrete a protein that alters the cellular binding of somatomedin-C/insulin-like growth factor I, J. Clin. Invest. 77:1548–1556 (1986).PubMedCrossRefGoogle Scholar
  4. 4.
    M.A. De Vroede, L.Y.-H. Tseng, P.G. Katsoyannis, S.P. Nissley, and M.M. Rechler, Modulation of insulinlike growth factor I binding to human fibroblast monolayer cultures by insulin-like growth factor carrier proteins released to the incubation media, J. Clin Invest. 77:602–613 (1986).CrossRefGoogle Scholar
  5. 5.
    R.G. Elgin, W.J. Busby Jr., and D.R. Clemmons, An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I, Proc. Natl. Acad. Sci. U.S.A. 84:3254–3258 (1987).PubMedCrossRefGoogle Scholar
  6. 6.
    D.R. Clemmons, V.K.M. Han, R.G. Elgin, and A.J. D’Ercole, Alterations in the synthesis of a fibroblast surfact associated 35K protein modulates the binding of somatomedin-C/insulin-like growth factor I, Mol. Endocrinol. 1:339–347 (1987).CrossRefGoogle Scholar
  7. 7.
    W.H. Busby Jr., D.G. Klapper, and D.R. Clemmons, Purification of a 31,000-Dalton insulin-like growth factor binding protein from human amniotic fluid, J. Biol. Chem. 263:14203–14210 (1988).Google Scholar
  8. 8.
    A.G. Frauman, S. Tsuzaki, and A.C. Moses, The binding characteristics and biologic effects in FRTL5 cells of placental protein-12, an insulin-like growth factor-binding protein purified from human amniotic fluid, Endocrinology 124:2289–2296 (1989).PubMedCrossRefGoogle Scholar
  9. 9.
    W.H. Busby, P. Hossenlopp, M. Binous, and D.R. Clemmons, Purified preparations of the amniotic fluid-derived insulin-like growth factor-binding protein contain multimeric forms that are biologically active, Endocrinology 125:773–777 (1989).PubMedCrossRefGoogle Scholar
  10. 10.
    R.S. Bar, B.A. Booth, M. Boes, and B.L. Dake, Insulinlike growth factor-binding proteins from vascular endothelial cells: Purification, characterization, and intrinsic biological activities, Endocrinology 125:1910–1920 (1989).PubMedCrossRefGoogle Scholar
  11. 11.
    D.R. Clemmons and L.I. Gardner, A factor contained in plasma is required for IGF binding protein-1 to potentiated the effect of IGF-I on smooth muscle cell DNA synthesis, J. Cell. Physiol. 145:129–135 (1990).PubMedCrossRefGoogle Scholar
  12. 12.
    R.H. McCusker, C. Camacho-Hubner, M.L. Bayne, M.A. Cascieri, and D.R. Clemmons, Insulin-like growth factor (IGF) binding to human fibroblast and glioblastoma cells: The modulatory effect of cell released IGF binding proteins (IGFBPs), J. Cell Physiol. 144:244–253 (1990).PubMedCrossRefGoogle Scholar
  13. 13.
    T.A. Bicsak, M. Shimonaka, M. Malkowski, and N. Ling,Insulin-like growth factor binding protein (IGF-BP) inhibition of granulosa cell function: Effect on cyclic adenosine 3’, 3’-monophosphate, deoxyribonucleic acid synthesis, and comparison with the effect of an IGF-I antibody, Endocrinology 126:2184–2189 (1990).PubMedCrossRefGoogle Scholar
  14. 14.
    M. Iu, M. Shimonaka, S. Shimasaki, and N. Ling, An insulin-like growth factor-binding protein in ovarian follicular fluid blocks follicle-stimulating hormone-stimulated steroid production by ovarian granulosa cells, Endocrinology 125:912–916 (1989).CrossRefGoogle Scholar
  15. 15.
    S. Shimasaki, M. Shimonaka, M. Ui, S. Inouye, F. Shibata, and N. Ling, Structural characterization of a follicle-stimulating hormone action inhibitor in porcine ovarian follicular fluid, J. Biol. Chem. 265:2198–2202 (1990).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Eli Y. Adashi
    • 1
  • C. E. Resnick
    • 1
  • R. G. Rosenfeld
    • 2
  • D. R. Powell
    • 3
  • R. Koistinen
    • 4
  • E. M. Rutanen
    • 4
    • 5
  • M. Seppala
    • 4
  1. 1.Division of Reproductive Endocrinology, Departments of Obstetrics, Gynecology, and PhysiologyUniversity of Maryland School of MedicineBaltimoreUSA
  2. 2.Department of PediatricsStanford University Medical CenterStanfordUSA
  3. 3.Department of PediatricsBaylor College of MedicineHoustonUSA
  4. 4.Department of Obstetrics/GynecologyHelsinki University Central HospitalHelsinkiFinland
  5. 5.Minerva Institute for Medical ResearchHelsinkiFinland

Personalised recommendations